Vanda Pharmaceuticals appoints chief commercial officer

Bob Repella joins US biopharmaceutical firm

Vanda Pharmaceuticals has named Bob Repella as senior vice president and chief commercial officer of the US biopharmaceutical firm that specialises in clinical-stage products for CNS disorders.

Repella has more than 25 years of experience in the biotech/pharmaceutical industry, including senior-level leadership roles in global marketing, sales, new product development and commercial operations.

Prior to joining Vanda, he was senior vice president of Pharmaceutical Operations for the Americas at Cephalon.

Before this, Repella was executive vice president and general manager of the Biopharma Business Unit for Wyeth Pharmaceuticals.

Earlier in his career, Repella held positions with Johnson & Johnson's McNeil Pharmaceutical Division, Merck & Co and Eli Lilly.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Regulatory

Latest EU drug approvals span range of health issues

Cancer was again at the forefront of the NMEs reaching the market in 2015, but new drugs also benefited other disease areas. Dr Sarah Houlton looks at the latest therapeutic arrivals
Regulatory

Sleep disorders – tasimelteon

Melatonin can be used to treat sleep disorders, but it has poor bioavailability, and has a half-life in the body of only about 15 minutes
Regulatory

Shilpa Medicare targets US approval for extended-release Ondansetron injection for CINV

Shilpa Medicare plans to pursue US approval and licensing partners for OERIS after a Phase III study in India met all primary and secondary endpoints and showed a strong safety profile in chemotherapy-induced nausea and vomiting
Manufacturing

MedPharm completes FDA inspection of manufacturing plant in Durham

The topical drug product manufacturing facility in North Carolina successfully completed its FDA inspection for the commercial manufacture of drug products with no Form 483 issued plus an NAI classification
Manufacturing

New thermal inkjet printer expands AM Labels’ coding portfolio

M2 system delivers high resolution variable data printing at production-line speeds
Pharmaceutical

Novo Nordisk launches the first oral GLP-1 in the US with new Wegovy pill

The new formulation of the obesity drug places Novo a step ahead of its competitor, Eli Lilly, whose rival drug orforglipron is still being assessed by regulators
Regulatory

Ascletis secures FDA IND clearance for Phase II Study of oral GLP-1 candidate in type 2 diabetes

Ascletis has received US FDA IND clearance to begin a 13-week Phase II trial of ASC30, its oral small-molecule GLP-1 receptor agonist, evaluating efficacy, safety and tolerability in people with type 2 diabetes
Subscribe now